Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05199896
Other study ID # 69HCL21_0882
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 20, 2022
Est. completion date October 2026

Study information

Verified date August 2022
Source Hospices Civils de Lyon
Contact Alessandro FARNE, Dr
Phone 04 72 91 34 17
Email alessandro.farne@inserm.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The use of tools is ubiquitous in our lives and allows us to expand the sensorimotor capacities of our body. Much research has been done on the subject in sighted people over the past decades. This work has mainly focused on the motor aspect of using the tool, neglecting the sensory aspect. However, any action involving a tool carries sensory information, for example in the use of the white cane by blind people. 26% (> 200,000) of blind people in France use a white cane to get around. By sweeping the cane on the ground, they use it as a sensorimotor extension of their body to extract information from the environment in order to locate a pedestrian crossing or possible obstacles. While it is well established that the tools increase the user's motor skills, we have only just begun to clarify how they also function as sensory extensions of the user's body and how this phenomenon is potentially dependent on constant use of the tool to compensate for a missing sense, as is the case with blind people using a cane. The aim of this study is to fill this important gap in our knowledge.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date October 2026
Est. primary completion date October 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Man or woman, aged 18 to 60 years old - Give an informed consent by signature - Be part of the national health security system (registered to the Securité Sociale) - do not confuse his right and his left Specific of the non-sighted participants: - Loss of vision happened at birth or 3-to 5 years later in life - Must have a visual acuity inferior or equal to 4/10 - Be with a close relation for read information letter and sign the consent form if needed Exclusion Criteria: - A person presenting an history of neurological, psychiatric or linguistic problems cannot be admitted - Assumption of psychotropic drugs - Pregnancy or breast-feeding woman - A person under legal tutoring - A person under care in other medical structure for reasons different from those of this research - A person under administrative or judiciary contention - A person who is not eligible to a MRI-exam according to the following criteria cannot be admitted to the experiments including MR acquisitions : - Have a neurological, cardiac (battery) or defibrillator pacemaker - Have a cardiac prosthesis (valve, stent...) or vascular prosthesis - Have intracranial clips or clamps - Carry a bypass of the cerebrospinal fluid - Having metallic splinters in the eyes - Wear metal prostheses (teeth, knees) - Wear an infusion pump or system - Be claustrophobic or have respiratory problems - Have metal tattoos close to the head - Have permanent make-up

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Behavioral protocol
A touch sensitive computer screen either displaying a downscaled (45cm long) image of the rod (for the sighted), or supporting a same sized wooden rod (for the blind), will be placed on the table in front of the participant to record their localization performance. They will be instructed to use their left index fingertip to indicate on the image of the screen (for sighted) or on the wooden rod (for the blind) the position where they have felt the touch provided to the 90 cm long they held in their right dominant hand. Participants will wear a headset playing white noise to prevent any auditory localization cues when the long rod will be touched. The rod will be touched by a computer controlled solenoid. Thus, participants will respond with a hand gesture on the image or rod and will be asked to validate the position by pressing a foot-pedal with their left foot.
Device:
EEG protocol
The EEG protocol will be similar as the behavioral one described above, with the distinction of taking place in two separate sessions: one where the rod are touched, and one where their hand is touched. The participant will hold a rod in each hand and he will have to indicate on which rod he felt the touch. Additionally electrophysiological responses will be continuously recorded using a 65 channel ActiCap system (Brain Products).
fMRI protocol
The same behavioral task and procedures of the behavioral protocol described above will be applied, adapted to take into account the constraints posed by the magnetic environment of the MR scanner. The participant will be placed on the scanner bed and provided with earphones that will both protect against the noise of the machine (80dB) and ensure a continuous communication with the participant. During the fMRI sessions, the participant will solve the same rod localization behavioral task while we will record brain activations by measuring the brain oxygen level dependent signal via Echo Planar Imaging sequences. We will use an MRI compatible tactile stimulator to touch the hand-held rod and participants location judgement will be recorded by using an MRI-compatible tablet, positioned on their abdomen, where the participant will have to indicate the judged position.

Locations

Country Name City State
France Equipe IMPACT du CRNL, Bâtiment INSERM Bron

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Perceived location Tactile stimulus will be applied on a tool (a rod). Subject should determine the exact spatial location of the stimulus.
This will be measure at each stimulation.
90 minutes
Secondary Brain activity Brain oscillatory activity and the somatosensory evoked potentials during the realization of experimental tasks on EEG.
Two sessions of about 3 hours are necessary for the EEG acquisition.
6 hours
Secondary Brain activity Measuring the brain oxygen level dependent (BOLD) signal during the realization of experimental tasks on fMRI 3 hours
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1